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ABSTRACT
Background Hepcidin is considered the master regulator of iron homoeostasis. Novel hepcidin antagonists
have recently been introduced as potential treatment for iron-restricted anaemia. Meanwhile, serum hepcidin
has been shown to be positively associated with cardiovascular disease and inversely with acute kidney injury.
These properties may lead to contrasting effects, especially in renal transplant recipients (RTR), which are prone
to cardiovascular diseases and graft failure. To date, the role of serum hepcidin in RTR is unknown. We,
therefore, prospectively determined the association of serum hepcidin with risk of graft failure, cardiovascular
mortality and all-cause mortality in RTR.
Materials and methods Serum hepcidin was assessed in an extensively phenotyped RTR cohort by dual-
monoclonal sandwich ELISA specific immunoassay. Statistical analyses were performed using univariate linear
regression followed by stepwise backward linear regression. Cox proportional hazard regression models were
performed to determine prospective associations.
Results We included 561 RTR (age 51  12 years). Mean haemoglobin (Hb) was 86  10 mM. Median [IQR]
serum hepcidin was 72 [32–134] ng/mL. Mean estimated glomerular filtration rate was 47  16 mL/min/
173 m2. In univariate Cox regression analyses, serum hepcidin was not associated with risk of graft failure,
cardiovascular mortality or all-cause mortality. Notably, after adjustment for high sensitivity C-reactive protein
and ferritin, serum hepcidin became negatively associated with all-cause mortality (hazard ratio 089; 95%
confidence interval 080–099, P = 003).
Conclusions In this study, we did not find an association between serum hepcidin and outcomes, that is graft
failure, cardiovascular mortality or all-cause mortality. Based on our results, it is questionable whether serum
hepcidin may be used to predict a beneficial effect of hepcidin antagonists.
Keywords Determinants, graft failure, hepcidin, mortality, renal transplantation.
Eur J Clin Invest 2016; 46 (12): 994–1001
Introduction
In renal transplant recipients (RTR), post-transplant anaemia is
associated with an increased risk for graft failure, cardiovas-
cular mortality and all-cause mortality. Iron deficiency is one of
the main contributors to post-transplant anaemia [1,2].
Hepcidin is known to be the master regulator of iron
homoeostasis [3,4]. The biologically active 25-amino acid form
of hepcidin (hepcidin-25) is mainly synthesized and secreted by
the liver and regulates the amount of iron absorbed from the
intestines and the iron release of the reticuloendothelial system
[5,6]. Hepcidin-25 regulates iron homoeostasis by binding
directly and causing internalization and degradation of
ferroportin, the iron transporter on the duodenal enterocytes
and macrophages [7,8].
In addition, serum hepcidin has been shown to be a potential
important biomarker for cardiovascular disease, because in
animals and humans, an association between serum hepcidin
and atherosclerotic disease and clinical events was found,
possibly mediated via iron sequestration [9]. In particular, in
chronic haemodialysis (HD) patients, serum hepcidin-25 has
been shown to be associated with fatal and nonfatal cardio-
vascular events [10].
Currently, hepcidin antagonists are being introduced as
potential treatment to improve iron-restrictive anaemia, such as
anaemia of inflammation, cancer or chronic kidney disease
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(CKD) [11–13]. Hepcidin antagonists may act on several path-
ways, that is neutralize hepcidin-stimulating cytokines (e.g. IL-
6), target the cytokine-signalling pathways, bind and neutralize
the hepcidin peptide (e.g. antibodies), prevent hepcidin bind-
ing to ferroportin or interfere with ferroportin-internalizing
pathways [14]. As a consequence, hepcidin antagonists may
interfere with post-transplant anaemia and beneficially influ-
ence graft and patient survival.
Hepcidin production is increased in response to high body
iron stores and inflammatory processes and decreased by low
circulatory iron and low iron body stores, via higher erythro-
poietin (EPO) activity and hypoxia [15]. In patients with CKD,
it is well established that serum hepcidin levels are elevated as
result of inflammation and possibly also due to diminished
renal clearance [16,17]. Moreover, it has been shown recently
that serum hepcidin is directly regulated by fasting insulin
levels [18]. To date, it is unknown in RTR to which degree
markers of iron availability (serum ferritin), inflammation [high
sensitivity C-reactive protein (hs-CRP)] and insulin sensitivity
(fasting insulin levels) determine the serum hepcidin level.
In the absence of prospective studies, we aimed to elucidate
the main determinants of serum hepcidin in RTR and to assess
the association of serum hepcidin with graft failure, cardio-
vascular mortality and all-cause mortality in RTR.
Materials and methods
Study design
All adult RTR who survived with a functioning allograft
beyond the first year after transplantation (1-year post-trans-
plantation was considered baseline) were eligible to participate
in this study during their next visit to the outpatient clinic.
Baseline data of the RTR were collected between August 2001
and July 2003 at a median 60 [interquartile range (IQR): 2–11]
years after transplantation. Combined transplant recipients (i.e.
kidney/pancreas or kidney/liver) were also invited to partici-
pate at the study. Patients with known or apparent systemic
illnesses (i.e. malignancies, opportunistic infections) were
excluded from participation. A total of 606 of 847 (72%) eligible
RTR gave informed consent for the study. For the analyses, we
excluded patients with missing data on hepcidin (n = 45),
resulting in 561 RTR eligible for analyses. Informed consent
was obtained in all participants, and approval for this study has
been obtained by the institutional review board (METc 2001/
039). Relevant donor, recipient and transplant characteristics
were extracted from the Groningen Renal Transplant Database,
which has been described in detail before [19].
Measurements
Blood was drawn in the morning after an 8- to 12-h overnight
fasting period to determine serum creatinine and plasma
glucose concentrations. Serum creatinine concentrations were
determined using the Jaffe method (MEGA AU510; Merck
Diagnostica, Darmstadt, Germany). Plasma glucose was mea-
sured by the glucose oxidase method (YSI 2300 Stat plus, Yel-
low Springs, OH, USA). Serum hepcidin was assessed by dual-
monoclonal sandwich ELISA immunoassay, as described in
detail previously [20]. Renal function was assessed by esti-
mating glomerular filtration rate (eGFR) applying the Chronic
Kidney Disease Epidemiology Collaboration equation [21].
Proteinuria was defined as ≥ 05 g protein/24 h urine. Blood
pressure was measured as the average of three automated
(Omron M4; Omron Europe B.V., Hoofddorp, the Netherlands)
measurements with 1-min intervals after a 6-min rest in supine
position. The primary end points of this study were death-
censored transplant failure, defined as return to dialysis ther-
apy or retransplantation, cardiovascular mortality and all-
cause mortality. The continuous surveillance system of the
outpatient programme ensures up-to-date information on
patient status. Follow-up was performed for a median of nearly
7 years. There was no loss due to follow-up for the primary
end points.
Statistical analyses
Data were analysed using IBM SPSS software, version 22.0 (SPSS
Inc., Chicago, IL, USA). Data are expressed as mean  SD
normally distributed variables and as median (IQR) for vari-
ables with a skewed distribution, for example hepcidin-25. In
cross-sectional analysis, one-way ANOVA was used for normally
distributed data and Kruskal–Wallis test for skewed dis-
tributed data. Multinomial chi-square test was used for
dichotomous or categorical data. Furthermore, univariate lin-
ear regression analysis was performed to assess the determi-
nants of serum hepcidin, which was followed by multivariate
linear regression analysis with a stepwise backward procedure.
For inclusion and exclusion in the multivariate linear regres-
sion analysis, P-values were set at 02 and 01, respectively. The
natural logarithm of hepcidin-25 was used as the dependent
variable in all regression models due to the skewed distribu-
tion. Other skewed distributed variables were also ln-trans-
formed for inclusion in regression analysis. To assess the
possible interaction and modification of a specific determinant
by another determinant, an interaction term was computed
and added to the univariate model and to the multivariate
model.
To study whether serum hepcidin was associated with risk of
graft failure, cardiovascular mortality and all-cause mortality,
Cox proportional hazards regression analyses were performed.
We performed analyses in which we adjusted for age and sex
(model 1), additionally for eGFR (model 2) and additionally for
hs-CRP and ferritin (model 3). Serum hepcidin was used as
categorical variable (tertiles) and as continuous variable to
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obtain the best fitting model; a 2 base of log-transformed values
was used to allow for expression of the hazard ratios (HR) per
doubling of serum hepcidin. Splines were fit by a Cox pro-
portional hazards regression model based on restricted cubic
splines and adjustments as in model 3. In all analyses, a two-
sided P-value < 005 was considered significant.
Results
Baseline characteristics
We included 561 stable RTR. Mean age was 51  12 years; 55%
of participants were male, and their body mass index (BMI)
averaged 260  43 kg/m2. Patients were included at 6.0
Table 1 Baseline characteristics of renal transplant recipients over tertiles of serum hepcidin
Variables
Tertiles of serum hepcidin
P-value1st tertile 2nd tertile 3rd tertile
Age (years) 51  12 50  13 53  11 003
Male sex (%) 51 57 56 052
Body mass index (kg/m2) 259  45 259  41 264  44 039
Body surface area (m2) 186  019 187  019 188  019 055
Never smoker (%) 36 37 34
Former smoker (%) 44 41 42 045
Current smoker (%) 19 22 23
Time since transplantation (years) 6.1 (2.8–10.9) 6.0 (3.3–11.8) 5.9 (2.3–11.9) 080
Alcohol use (%) 48 56 54 031
Diabetes (%) 18 18 16 073
Systolic blood pressure (mmHg) 156  23 151  22 152  23 011
Diastolic blood pressure (mmHg) 91  10 90  9 89  10 005
Laboratory measurements
Hepcidin (ng/mL) 21 (09–33) 73 (58–89) 165 (134–253) –
hs-CRP (mg/L) 15 (07–39) 18 (06–42) 28 (12–74) < 0001
Albumin (g/L) 404  30 412  30 404  33 002
Total protein (g/L) 670  44 676  45 671  51 043
Total cholesterol (mM) 55  10 56  09 57  13 020
Creatinine (lM) 129 (109–157) 133 (114–155) 139 (115–192) 001
eGFR (mL/min/173 m2) 485  158 492  146 433  163 < 0001
HbA1c (mmol/mol) 468  120 470  115 488  111 019
Insulin (lU/mL) 120 (85–175) 122 (80–147) 108 (76–168) 006
Haemoglobin (mM) 87  10 87  09 84  10 < 0001
MCV (fL) 902  70 923  56 910  69 0007
Ferritin (lg/L) 70 (38–112) 171 (108–258) 291 (177–452) < 0001
NT-pro-BNP (pg/mL) 291 (144–683) 268 (104–544) 354 (139–706) 006
EPO (IU/L) 20 (13–28) 17 (12–23) 16 (11–23) 001
hs-CRP, high sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; HbA1c, hemoglobin A1c; MCV, mean corpuscular
volume; NT-pro-BNP, N-terminal prohormone of brain natriuretic peptide.
A P-value across tertiles of serum hepcidin was calculated with an one-way ANOVA for normally distributed data, and with a Kruskal–Wallis test for skewed
distributed data. Chi-square test was used for dichotomous or categorical data. Alcohol use was defined as alcohol consumers vs. abstainers.
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(2.6–11.5) years after transplantation. Serum hepcidin-25 con-
centrations were 72 (32–134) ng/mL, haemoglobin concen-
trations were 86  10 mM, hs-CRP concentrations were 20
(08–48) mg/L, and ferritin concentrations were 1560 (780–
2830) lg/L. Across tertiles of serum hepcidin, significant dif-
ferences were noted in hs-CRP, serum albumin, serum crea-
tinine, eGFR, haemoglobin, mean corpuscular volume (MCV),
ferritin, and EPO concentrations (Table 1).
Determinants of serum hepcidin
In univariate regression analysis, ferritin (b = 069, P < 0001,
Fig. 1), hs-CRP (b = 024, P < 0001), eGFR (b = 014,
P = 0001), Hb (b = 012, P = 0006), EPO (b = 012,
P = 0006), fasting insulin (b = 009, P = 003) and age
(b = 009, P = 003) were associated with serum hepcidin.
In multivariate regression analysis, ferritin (b = 066,
P < 0001), hs-CRP (b = 019, P < 0001), EPO (b = 013,
P < 0001), fasting insulin (b = 008, P = 001) and Hb
(b = 006, P = 006; total model R2 = 053) were identified as
independent determinants of serum hepcidin, while the uni-
variate association of eGFR was lost (Table 2). To assess
specifically which additional determinant caused that eGFR
lost the association with serum hepcidin, we analysed adding
all separate determinants of the multivariate model in combi-
nation with eGFR. The association of eGFR with serum hep-
cidin disappeared after inclusion of serum ferritin in the model
(b = 005, P = 011).
An interaction term between hs-CRP and serum ferritin was































Relationship between insulin, ferritin and hepcidin levels 
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Figure 1 Determinants of serum hepcidin. (a) The interaction
between high sensitivity C-reactive protein (hs-CRP) and serum
ferritin on hepcidin is shown. hs-CRP and ferritin levels were
divided in tertiles. (b) The interaction between serum insulin
levels and serum ferritin on serum hepcidin is shown. Insulin
and ferritin levels were divided in tertiles.







Std. b P-value Std. b P-value
Age (years) 009 003
Male sex 001 077




Albumin (g/L) 002 065
HbA1c (mmol/mol) 007 010
Insulin (lU/mL) 009 003 008 001
Glucose (mM) 007 010
Smoking (yes vs no) 003 049
Alcohol use (yes vs no) 001 078
hs-CRP (mg/L) 024 < 0001 019 < 0001
Creatinine (lM) 013 0003
eGFR (mL/min/173 m2) 014 0001
Ferritin (lg/L) 069 < 0001 066 < 0001
Haemoglobin (mM) 012 0006 006 006
EPO (IU/L) 012 0006 013 < 0001
NT-pro-BNP (pg/mL) 005 027
Total cholesterol (mM) 011 0007
Total protein (g/L) 0009 083
BMI, body mass index; hs-CRP, high sensitivity C-reactive protein; eGFR,
estimated glomerular filtration rate; EPO, erythropoietin; NT-pro-BNP, N-
terminal prohormone of brain natriuretic peptide.
Univariate and multivariate linear regression analyses of potential determi-
nants of serum hepcidin concentrations. Smoking was defined as current use
of cigarettes.
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(P = 001). When adding the interaction to the multivariate
model, still a significant interaction was present (P = 0.02). The
relation between serum ferritin and serum hepcidin was pre-
sent irrespective of inflammation reflected by hs-CRP concen-
tration (Fig. 1a). Moreover, the higher the hs-CRP concentration
at lower levels of serum ferritin, the higher the serum hepcidin
levels. Also, an interaction between insulin concentrations and
serum ferritin concentrations was noted (P = 0005). When
adding the interaction term to the multivariate model, the
interaction term remained a determinant of serum hepcidin
(Fig. 1b; P = 002).
Prospective analyses
During a median follow-up of 69 (IQR: 62–72) years, 50 RTR
experienced graft failure, 61 died due to a cardiovascular event,
and in total, 119 RTR died. Next to the 61 cardiovascular deaths
(51%), other causes of death were 19 infection (16%), 26
malignancy (22%) and 12 miscellaneous and other causes
(10%).
In Cox regression analysis, serum hepcidin as continuous
variable was not significantly associated with graft failure,
cardiovascular mortality and all-cause mortality in age- and
sex-adjusted analysis (Table 3). However, after adjustment for
ferritin and hs-CRP, the association of serum hepcidin as con-
tinuous variable with all-cause mortality became inversely
significant (HR 084; 95% confidence interval (CI) 072–098,
P = 003), whereas the association of serum hepcidin with car-
diovascular mortality and graft failure remained nonsignificant
(Fig. 2).
When divided in tertiles, serum hepcidin was not signifi-
cantly associated with graft failure, cardiovascular mortality
and all-cause mortality in age- and sex-adjusted analysis.
However, after adjustment for ferritin and hs-CRP, the upper
tertile of serum hepcidin was strongly associated with a
decreased risk of cardiovascular mortality (HR 036; 95% CI
018–073, P = 0005) and all-cause mortality (HR 048; 95% CI
029–079, P = 0004; Table 3).
Discussion
This study, in stable RTR patients with a large variation in
kidney function, did not show an association of serum hepcidin
with graft failure, cardiovascular mortality and all-cause mor-
tality in age- and sex-adjusted analysis. This is in contrast with
results from other populations where serum hepcidin has been
shown to be associated with increased risk for cardiovascular
events as well as all-cause mortality, and with a protective
effect on kidney function [9,22–25].
As expected, serum hepcidin-25 levels were mainly deter-
mined by iron stores (as reflected by serum ferritin),
Table 3 Prospective analysis serum hepcidin on graft failure, cardiovascular mortality, and all-cause mortality in renal transplant
recipients
Tertiles of hepcidin, ng/mL
Serum hepcidin as continuous
variable (2log), ng/mL
Reference HR (95% CI) HR (95% CI)
HR (95% CI) P value< 444 444–1076 > 1076
Graft failure
Model 1 100 068 (031–148) 177 (092–339) 120 (100–144) 005
Model 2 100 080 (037–177) 091 (046–179) 101 (086–118) 096
Model 3 100 079 (035–176) 081 (040–163) 099 (084–117) 088
Cardiovascular mortality
Model 1 100 075 (040–139) 072 (039–133) 104 (090–119) 063
Model 2 100 077 (041–142) 062 (034–116) 100 (087–115) 099
Model 3 100 059 (031–114) 036 (018–074) 089 (077–103) 011
All-cause mortality
Model 1 100 067 (043–105) 075 (049–115) 100 (091–110) 094
Model 2 100 069 (044–108) 064 (041–098) 095 (087–105) 033
Model 3 100 063 (039–101) 048 (029–079) 089 (080–099) 003
Model 1: Adjustment for age and sex.
Model 2: Model 1+ additional adjustment for estimated glomerular filtration rate.
Model 3: Model 2+ additional adjustment for hs-C-reactive protein and ferritin.
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inflammation (as reflected by hs-CRP levels), tissue hypoxia
(which is the primary stimulus for and reflected by increased
EPO levels), insulin sensitivity (as reflected by fasting insulin
levels) and serum haemoglobin. These factors accounted for
53% of the variance in the level of serum hepcidin in the pre-
sent study.
As hepcidin antagonists are currently introduced as
potential treatment for iron-restricted anaemia [13], we
deemed it clinically relevant to assess whether increased
serum hepcidin levels were associated with renal graft failure,
cardiovascular mortality and all-cause mortality. Hepcidin-25
has been shown to predict cardiovascular events in chronic
HD patients [10]. It has been postulated that increased hep-
cidin concentrations are associated with arteriosclerotic dis-
ease by retaining iron in macrophages in the vascular wall.
This intracellular iron sequestration may result in pro-
atherogenic environment mediated by oxidative stress,
inflammatory responses and macrophage apoptosis [9,15].
Moreover, it has been shown that hepcidin-25 in diabetic
patients with CKD is associated with mortality [22]. We found
no such relationship in RTR. However, after adjustment for
serum ferritin and hs-CRP, serum hepcidin was inversely
associated with cardiovascular mortality and all-cause mor-
tality. As a consequence, it may be speculated that under
circumstances where hepcidin reflects mainly lack of hypoxia
or lack of anaemia [as it is corrected for iron load (serum
ferritin) and inflammation (hs-CRP)], it may convey a pro-
tective effect [18,23,26].
Next to the association with cardiovascular mortality and all-
cause mortality, we assessed the association of serum hepcidin
with renal risk. Wagner et al. [22] found elevated hepcidin-25
levels to be predictive of progression of CKD, whereas van
Swelm et al. [23] recently suggested that hepcidin protects
against haemoglobin-induced acute kidney injury. In our
study, we did not find an association of serum hepcidin with
risk of graft failure.
With respect to the determinants of serum hepcidin in our
cohort of RTR, as expected, serum ferritin was the strongest
determinant of serum hepcidin. Serum ferritin has already been
acknowledged to be a major determinant of serum hepcidin in
other populations, for example healthy controls, patients with
CKD and HD patients [16,27–29]. In RTR, serum ferritin has
been shown to be an important determinant of serum hepcidin
in smaller cohorts [30]. As serum ferritin is also an acute phase
reactant, inflammation can elevate serum ferritin, which could
be a cause of high correlation with serum hepcidin in RTR.
However, after inclusion of hs-CRP in the model, the associa-
tion with serum ferritin remained. Taken the results of the
models in Table 2 together, it seems that serum hepcidin levels
in RTR are mainly determined by inflammation and iron status.
Additionally, we found that serum hepcidin concentrations are
inversely associated with fasting insulin levels because in the
interaction at low serum ferritin, higher serum insulin levels are
associated with lower serum hepcidin levels [18]. These find-
ings underline the close relationship of markers of iron meta-
bolism and insulin resistance which has been recently been
evaluated by Krisai et al.[31].
The present study has several limitations. We used serum
ferritin as a marker of iron availability. Although ferritin is the
most frequently used marker of iron status both experimentally
and clinically, it is also upregulated by inflammation [32]. Pos-
sibly, a combination with transferrin saturation or percentage
hypochromic red blood cells would reflect better iron status than
serum ferritin alone [33]. However, these data are not available.
Another limitation is that our study is a single-centre experience.
The most important strength of our study is that as far as we
know, we are to date the first who assessed the prospective
association of serum hepcidin in RTR with outcomes, that is













































































































Figure 2 Association between serum hepcidin and risk of graft failure (a) of cardiovascular (b) and all-cause mortality (c) according
to model 3, Table 3. The line in the graph represents the hazard ratio. The grey area represents the 95% confidence interval of the
hazard ratio.
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graft failure, cardiovascular mortality, and all-cause mortality.
Moreover, our study comprises the largest cohort of RTR where
serum hepcidin levels have been determined so far [34,35].
Another strength of this study is the dual-monoclonal sand-
wich ELISA that has been used to determine serum hepcidin,
which has been shown to be highly specific and to correlate
robustly well with the gold standard, liquid chromatography–
mass spectrometry assay for serum hepcidin-25 [20].
In conclusion, we did not find an association between serum
hepcidin and prospective outcomes, that is graft failure, car-
diovascular mortality or all-cause mortality with serum hep-
cidin concentrations in RTR being mainly determined by iron
status and inflammation. Taken these findings together, it is
questionable that serum hepcidin levels may be used to predict
the potential beneficial effect of hepcidin antagonists in RTR.
Further studies are needed to validate these results and to
evaluate whether there is a potential role for hepcidin antago-
nists to improve iron deficiency, anaemia and outcome in RTR.
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